These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8814313)

  • 21. Identification of a novel inhibitor of LPS-induced TNF-alpha production with antiproliferative activity in monocyte/macrophages.
    Nagahira A; Nagahira K; Murafuji H; Abe K; Magota K; Matsui M; Oikawa S
    Biochem Biophys Res Commun; 2001 Mar; 281(4):1030-6. PubMed ID: 11237767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipopolysaccharide induces expression of tumour necrosis factor alpha in rat brain: inhibition by methylprednisolone and by rolipram.
    Buttini M; Mir A; Appel K; Wiederhold KH; Limonta S; Gebicke-Haerter PJ; Boddeke HW
    Br J Pharmacol; 1997 Dec; 122(7):1483-9. PubMed ID: 9421299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia.
    Spond J; Chapman R; Fine J; Jones H; Kreutner W; Kung TT; Minnicozzi M
    Pulm Pharmacol Ther; 2001; 14(2):157-64. PubMed ID: 11273798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Viral IL-10 gene therapy inhibits TNF-alpha and IL-1 beta, not IL-6, in the newborn endotoxemic mouse.
    Drazan KE; Wu L; Bullington D; Shaked A
    J Pediatr Surg; 1996 Mar; 31(3):411-4. PubMed ID: 8708914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice.
    Liang L; Beshay E; Prud'homme GJ
    Diabetes; 1998 Apr; 47(4):570-5. PubMed ID: 9568689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
    Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
    Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of mitogen-activated protein kinase inhibitors or phosphodiesterase inhibitors on interleukin-1-induced cytokines production in synovium-derived cells.
    Tsuji F; Oki K; Senda T; Horiuchi M; Mita S
    Immunol Lett; 1999 Jun; 68(2-3):275-9. PubMed ID: 10424432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
    Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
    Underwood DC; Osborn RR; Kotzer CJ; Adams JL; Lee JC; Webb EF; Carpenter DC; Bochnowicz S; Thomas HC; Hay DW; Griswold DE
    J Pharmacol Exp Ther; 2000 Apr; 293(1):281-8. PubMed ID: 10734180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential regulation of lipopolysaccharide-induced interleukin 1 and tumor necrosis factor synthesis: effects of endogenous and exogenous glucocorticoids and the role of the pituitary-adrenal axis.
    Zuckerman SH; Shellhaas J; Butler LD
    Eur J Immunol; 1989 Feb; 19(2):301-5. PubMed ID: 2784766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions.
    Barnette MS; Christensen SB; Essayan DM; Grous M; Prabhakar U; Rush JA; Kagey-Sobotka A; Torphy TJ
    J Pharmacol Exp Ther; 1998 Jan; 284(1):420-6. PubMed ID: 9435206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-alpha synthesis.
    Greten TF; Sinha B; Haslberger C; Eigler A; Endres S
    Eur J Pharmacol; 1996 Mar; 299(1-3):229-33. PubMed ID: 8901027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids.
    Sinha B; Semmler J; Eisenhut T; Eigler A; Endres S
    Eur J Immunol; 1995 Jan; 25(1):147-53. PubMed ID: 7843225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
    Wadsworth SA; Cavender DE; Beers SA; Lalan P; Schafer PH; Malloy EA; Wu W; Fahmy B; Olini GC; Davis JE; Pellegrino-Gensey JL; Wachter MP; Siekierka JJ
    J Pharmacol Exp Ther; 1999 Nov; 291(2):680-7. PubMed ID: 10525088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
    Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
    Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of rolipram in a murine model of acute inflammation: comparison with the corticoid dexamethasone.
    Klemm P; Harris HJ; Perretti M
    Eur J Pharmacol; 1995 Jul; 281(1):69-74. PubMed ID: 8566119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram.
    Ross SE; Williams RO; Mason LJ; Mauri C; Marinova-Mutafchieva L; Malfait AM; Maini RN; Feldmann M
    J Immunol; 1997 Dec; 159(12):6253-9. PubMed ID: 9550429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
    Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
    J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of rolipram, a selective inhibitor of type 4 phosphodiesterase, on lipopolysaccharide-induced uveitis in rats.
    Chi ZL; Hayasaka S; Zhang XY; Hayasaka Y; Cui HS
    Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2497-502. PubMed ID: 15277469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection by a cyclic AMP-specific phosphodiesterase inhibitor, rolipram, and dibutyryl cyclic AMP against Propionibacterium acnes and lipopolysaccharide-induced mouse hepatitis.
    Taguchi I; Oka K; Kitamura K; Sugiura M; Oku A; Matsumoto M
    Inflamm Res; 1999 Jul; 48(7):380-5. PubMed ID: 10450787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.